Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2023-06-15
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis
NCT02717871
Tacrolimus Eye Drops in Treatment of Vernal Keratoconjunctivitis
NCT07138742
Au-Ag-Cu2O NG With PTT Anti Drug-resistant Microbial Keratitis
NCT05268718
The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study
NCT05655689
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers
NCT05255016
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
groupA (control group)
will include 20 eyes of 20 patients with infectious keratitis who will receive antimicrobial therapy.
Antibotice.g vigamox ED Antifungal e.g Dflucan
topical application of antimicropial therapy
group B
will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated cross-linking Protocol-1 (9 mW/cm2 for 10 minutes to achieve 5.4 J/cm2) followed by antimicrobial therapy
Riboflavin
topical application of riboflavin followed by cross linking
Antibotice.g vigamox ED Antifungal e.g Dflucan
topical application of antimicropial therapy
pack cross linking
TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS
group C
will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated crosslinking Protocol-2 (18 mW/cm2 for 7 minutes to achieve 7.2 J/cm2) followed by antimicrobial therapy
Riboflavin
topical application of riboflavin followed by cross linking
Antibotice.g vigamox ED Antifungal e.g Dflucan
topical application of antimicropial therapy
pack cross linking
TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Riboflavin
topical application of riboflavin followed by cross linking
Antibotice.g vigamox ED Antifungal e.g Dflucan
topical application of antimicropial therapy
pack cross linking
TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mariam Abdelmawgoud Mohamed
assistant lecteurer opthalmology department sohag univerisity hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag University Hospital
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
mohamed i hafez, professor
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
magdy m ameen, professor
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Cabrera-Aguas M, Khoo P, Watson SL. Infectious keratitis: A review. Clin Exp Ophthalmol. 2022 Jul;50(5):543-562. doi: 10.1111/ceo.14113. Epub 2022 Jun 3.
Papaioannou L, Miligkos M, Papathanassiou M. Corneal Collagen Cross-Linking for Infectious Keratitis: A Systematic Review and Meta-Analysis. Cornea. 2016 Jan;35(1):62-71. doi: 10.1097/ICO.0000000000000644.
Tabibian D, Mazzotta C, Hafezi F. PACK-CXL: Corneal cross-linking in infectious keratitis. Eye Vis (Lond). 2016 Apr 19;3:11. doi: 10.1186/s40662-016-0042-x. eCollection 2016.
Kumar V, Lockerbie O, Keil SD, Ruane PH, Platz MS, Martin CB, Ravanat JL, Cadet J, Goodrich RP. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004 Jul-Aug;80:15-21. doi: 10.1562/2003-12-23-RA-036.1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pack cross linking
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.